A patient with metastatic BC with FGFR3-TACC3 fusion showed a remarkable response to sequential treatment with FGFR3 inhibition and anti-PD-L1 blockade, underscoring the potential synergy between FGFR inhibitors and ICIs in this molecular subgroup [21]. Here, TACC3 is linked to breast cancer.